Log In
Print
BCIQ
Print
Print this Print this
 

Zytiga (abiraterone acetate) (CB7630)

  Manage Alerts
Collapse Summary General Information
Company BTG plc
DescriptionInhibitor of cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17)
Molecular Target Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A)
Mechanism of ActionCytochrome P450 17alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationProstate cancer
Indication DetailsNeoadjuvant treatment in patients with localized high-risk prostate cancer; Treat advanced prostate cancer; Treat castration-resistant prostate cancer (CRPC); Treat chemotherapy-naïve castration-resistant prostate cancer (CRPC); Treat chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly asymptomatic after failing androgen deprivation therapy; Treat high-risk metastatic hormone-naive prostate cancer (mHNPC); Treat metastatic castration-resistant prostate cancer (CRPC); Treat patients with metastatic, CRPC who are asymptomatic or mildly asymptomatic after failing androgen deprivation therapy; Treat prostate cancer
Regulatory Designation U.S. - Priority Review (Treat patients with metastatic, CRPC who are asymptomatic or mildly asymptomatic after failing androgen deprivation therapy);
U.S. - Special Protocol Assessment (Treat metastatic castration-resistant prostate cancer (CRPC));
Japan - Standard Review (Treat prostate cancer)
Partner AstraZeneca plc; Johnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,000.0M

$1,000.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today